solute carrier family 19 member 1Genealiases: CHMD · FOLT · IFC-1 · IFC1 · IMD114 · MEGAF
Q-omics provides the consensus-scored SLC19A1 profile across patient tissues and cancer cell-line models. SLC19A1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC19A1 is differentially expressed in 18, with the highest sampling consensus in BLCA. Additionally, SLC19A1 RNA expression shows 18,194 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where SLC19A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC19A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC19A1 survival associations across molecular data types. SLC19A1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC19A1 RNA expression–survival associations across cancer types. High SLC19A1 expression shows unfavorable associations in KIRC, MESO, ACC, KIRP, UVM and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC19A1 RNA expression.
This table summarizes SLC19A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC19A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC19A1 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, KIRC, COAD and KIRP. The BLCA box plot shows higher SLC19A1 RNA expression in tumor versus normal tissue (log2 FC = +1.784, t-test p < 0.001).
This table shows molecular features associated with SLC19A1 in patient tissues and cancer cell lines. In patient samples, SLC19A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC19A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and PANCREAS.
